Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli Lilly began marketing its rival product Mounjaro in the world's most populous nation.

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite competitor Eli Lilly’s early mover advantage, and future competition from cheaper generics.

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.